Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Ziprasidone, a new atypical antipsychotic drug
Autore:
Carnahan, RM; Lund, BC; Perry, PJ;
Indirizzi:
Univ Iowa, Coll Pharm, Clin & Adm Pharm Div, Iowa City, IA 52242 USA Univ Iowa Iowa City IA USA 52242 & Adm Pharm Div, Iowa City, IA 52242 USA Univ Iowa, Coll Med, Dept Psychiat, Iowa City, IA 52242 USA Univ Iowa Iowa City IA USA 52242 , Dept Psychiat, Iowa City, IA 52242 USA
Titolo Testata:
PHARMACOTHERAPY
fascicolo: 6, volume: 21, anno: 2001,
pagine: 717 - 730
SICI:
0277-0008(200106)21:6<717:ZANAAD>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLACEBO-CONTROLLED TRIAL; SCHIZOAFFECTIVE DISORDER; ACUTE EXACERBATION; DOUBLE-BLIND; WEIGHT-GAIN; SCHIZOPHRENIA; HALOPERIDOL; ADOLESCENTS; OLANZAPINE; DOPAMINE;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
45
Recensione:
Indirizzi per estratti:
Indirizzo: Perry, PJ Univ Iowa, Coll Pharm, Clin & Adm Pharm Div, S415 Pharm Bldg, Iowa City, IA 52242 USA Univ Iowa S415 Pharm Bldg Iowa City IA USA 52242 y, IA 52242 USA
Citazione:
R.M. Carnahan et al., "Ziprasidone, a new atypical antipsychotic drug", PHARMACOTHE, 21(6), 2001, pp. 717-730

Abstract

Although the introduction of antipsychotic drugs in 1954 was a breakthrough in the treatment of patients with schizophrenia, these agents have a number of adverse effects that limit effectiveness and compliance. The atypicalantipsychotic drugs provide an improved tolerability profile, particularlyin minimizing extrapyramidal side effects; however, they are associated with significant weight gain, which may be related to growing evidence linking the atypical agents with diabetes and hyperlipidemia. Ziprasidone, a new atypical antipsychotic drug, was demonstrated in clinical trials to be moreefficacious than placebo and similar in efficacy to haloperidol in the treatment of schizophrenia. Like the existing atypical agents, ziprasidone hasa rate of extrapyramidal side effects similar to that of placebo and does not cause significant elevations in prolactin levels. In contrast, ziprasidone has a low propensity for causing weight gain. For patients requiring anantipsychotic drug, ziprasidone represents a new treatment option with a limited adverse effect profile.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 07:37:02